Possible Approval of First DMD Gene Therapy Creates Buzz at MDA Conference
DALLAS, Texas—Despite a late-stage regulatory hiccup, pharmaceutical executives and patient advocates at a neuromuscular disease meeting here predict the US Food and Drug Administration (FDA) will still approve the first-ever gene therapy for Duchenne muscular dystrophy (DMD) as expected on May 29, 2023. SRP-9001 (delandistrogene moxeparvovec), developed by Sarepta Therapeutics, was easily the chief topic…